Published on 3 Oct 2023 on Zacks via Yahoo Finance
Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans
Accuray Incorporated ARAY recently unveiled an online adaptive therapy option, Cenos, for its Radixact System. The solution was unveiled, in partnership with Limbus AI, at the ongoing 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting.
However, the FDA’s 510(k) clearance is currently pending. Also, the solution is not presently available for sale in the United States and is not CE-marked. Hence, the availability is subject to regulatory clearance or approval in some markets.
The latest offering is expected to significantly strengthen Accuray’s TomoTherapy platform on a global scale.